Additionally, olaparib has gained approval from the US FDA for the adjuvant treatment of high‐risk, HER2‐negative breast cancer patients carrying germline BRCA1/2 mutations who have undergone neoadjuvant or adjuvant chemotherapy.44 This evidence concerns the gene ERBB2 and breast carcinoma.